We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Hutchmed (China) Limited 20 November 2024 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee Hong Kong, Shanghai & Florham Park, NJ...
Hutchmed (China) Limited 06 November 2024 Press Release HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress Hong Kong...
Hutchmed (China) Ltd on Thursday said it will receive a USD20 million payment from its partner Takeda Pharmaceutical ...
Hutchmed (China) Limited 31 October 2024 Press Release HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda ...
Hutchmed (China) Limited 31 October 2024 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ – Thursday, October 31, 2024: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:...
Hutchmed (China) Limited 21 October 2024 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ - Monday, October 21, 2024: HUTCHMED (China) Limited...
Hutchmed China Ltd on Wednesday said that Tagrisso plus Orpathys showed a high clinically meaningful response rate in ...
Hutchmed (China) Limited 16 October 2024 HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of...
Takeda Pharmaceutical Co Ltd on Tuesday said it landed an approval for its Fruzaqla drug in Japan. The drug has bee ...
Hutchmed (China) Limited 24 September 2024 HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - Approval based on results from global Phase III FRESCO-2...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 11 | 4.10447761194 | 268 | 290 | 260 | 59536 | 272.03316671 | DE |
4 | -57 | -16.9642857143 | 336 | 336 | 260 | 67063 | 291.31968388 | DE |
12 | 6 | 2.1978021978 | 273 | 336 | 242 | 139840 | 295.19971089 | DE |
26 | -33 | -10.5769230769 | 312 | 336 | 242 | 99745 | 294.63179424 | DE |
52 | -17 | -5.74324324324 | 296 | 353 | 190.4 | 88901 | 287.58880592 | DE |
156 | -191 | -40.6382978723 | 470 | 556 | 130 | 105330 | 273.87711253 | DE |
260 | -89 | -24.1847826087 | 368 | 656 | 130 | 101730 | 348.86820717 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions